Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration TREX-AMD 1-Year Results by Wykoff, Charles C. et al.
Prospective Trial of Treat-and-Extend versus
Monthly Dosing for Neovascular Age-Related
Macular Degeneration
TREX-AMD 1-Year Results
Charles C. Wykoff, MD, PhD,1,2 Daniel E. Croft, BA,1 David M. Brown, MD,1,2 Rui Wang, BA,1
John F. Payne, MD,3 Lloyd Clark, MD,3 Nizar Saleh Abdelfattah, MD,4,5 SriniVas R. Sadda, MD,4,5
on behalf of the TREX-AMD Study Group*
Purpose: To assess prospectively a treat-and-extend (TREX) management strategy compared with monthly
dosing of intravitreal ranibizumab in treatment-naïve neovascular age-related macular degeneration (AMD)
patients.
Design: Phase IIIb, multicenter, randomized, controlled clinical trial.
Participants: Sixty patients with treatment-naïve neovascular AMD randomized 1:2 to monthly or TREX
management.
Methods: Patients with Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity
(BCVA) from 20/32 to 20/500 (Snellen equivalent) were randomized to receive intravitreal 0.5 mg ranibizumab
monthly or according to a TREX protocol. The TREX patients were treated monthly for at least 3 doses, until
resolution of clinical and spectral-domain optical coherence tomography evidence of exudative disease activity;
the interval between visits then was individualized according to a strict prospective protocol.
Main Outcome Measures: Mean ETDRS BCVA change from baseline.
Results: At baseline, mean age was 77 years (range, 59e96 years), mean BCVA was 20/60 (Snellen
equivalent), and mean central retinal thickness (CRT) was 511 mm. Fifty-seven eyes (95%) completed month 12, at
which point mean BCVA improved by 9.2 and 10.5 letters in the monthly and TREX cohorts, respectively (P ¼
0.60). The mean number of injections administered through month 12 was 13.0 and 10.1 (range, 7e13) in the
monthly and TREX cohorts, respectively (P < 0.0001). Among TREX patients, 7 (18%) were maximally extended, 4
(10%) demonstrated ﬂuid at every visit, and at month 12, 18 (45%) had achieved an extension interval of 8 weeks
or more; the mean maximum extension interval between injections after the ﬁrst 3 monthly doses was 8.4 weeks
(range, 4e12 weeks). Most TREX patients who demonstrated recurrent exudative disease activity (17/24 [71%])
were unable to extend beyond their initial maximum extension interval.
Conclusions: The TREX neovascular AMD management strategy used in this prospective, randomized,
controlled trial resulted in visual and anatomic gains comparable with those obtained with monthly
dosing. Ophthalmology 2015;122:2514-2522 ª 2015 by the American Academy of Ophthalmology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
*Supplemental material is available at www.aaojournal.org.Neovascular age-related macular degeneration (AMD) is a
leading cause of vision loss, with approximately 200 000 new
diagnoses each year in the United States.1 Pharmaceutical
agents, including the Food and Drug Administration-
approved options ranibizumab (Lucentis; Genentech, Inc.,
South San Francisco, CA)2 and aﬂibercept (Eylea; Regeneron,
Inc., Tarrytown, NJ),3 as well as the off-label option bev-
acizumab (Avastin; Genentech, Inc.),4 all block vascular
endothelial growth factor (VEGF) A. These agents have
revolutionized neovascular AMD management, and disease
stability along with visual improvements can be achieved in2514  2015 by the American Academy of Ophthalmology
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). Published by Elsevier Incmost patients with treatment.2e4 The landmark trials
illustrating these beneﬁts have used 3 management strate-
gies: monthly dosing,2e4 every other month dosing after
3 initial monthly doses,3 or monthly visits with pro re nata
(PRN) re-treatment on evidence of exudative disease
activity.4,5
Prospective trials comparing ﬁxed-interval dosing with
PRN dosing consistently have demonstrated optimal visual
outcomes with monthly dosing.4,5 Use of PRN dosing
permits repeated recurrences of exudative disease activity,
as illustrated by intraretinal or subretinal ﬂuid. This.
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Figure 1. Treat-and-extend case example. A, Baseline fundus photograph with spectral-domain (SD) optical coherence tomography (OCT) orientation
(green line), followed by sequential SD OCT images at baseline, visit 4 (week 32), and visit 8 (month 12), illustrating recurrence of subretinal ﬂuid (visit 4)
and resolution of subretinal ﬂuid (visit 8). B, Graph showing that as soon as the macula is dry, the treatment interval is sequentially increased by 2 weeks
until recurrent exudation is identiﬁed (visit 4). The interval is reduced until dry, then extended by a 1-week interval, and recurrent exudation is identiﬁed
again (visit 6), and the interval again is reduced. BCVA ¼ best-corrected visual acuity; ETDRS ¼ Early Treatment Diabetic Retinopathy Study.
Wykoff et al  TREX-AMD 1-Year Resultsrecurrent disease activity is a marker for worse visual
outcomes compared with a dry, exudate-free macula.6
Despite this, PRN management achieves substantial
clinical beneﬁts while reducing treatment burden by
approximately 3 to 4 injections in the ﬁrst year alone.4,5
Additionally, PRN trials have revealed considerable vari-
ability in the required number of injections,7 indicating that
treatment tailored to an individual’s clinical response may
be optimal. Underscoring this concept, intraocular levels of
VEGF can vary among patients with phenotypically
similar disease states.8
A treat-and-extend (TREX) protocol uses monthly in-
jections until signs of exudation have resolved.9 Then, the
interval between treatments is lengthened, typically
sequentially by 1- to 2-week intervals as long as there are
no signs of recurrent exudation. Treatment is rendered at
every visit and the time between visits is individualized.
When recurrent disease is detected, the treatment interval is
reduced. The goal is to maintain an exudation-free macula
and to avoid multiple disease recurrences, as occurs with
PRN dosing, while minimizing treatment burden through
fewer clinical visits, diagnostics, and treatments.
Many retrospective and observational studies have
supported a TREX approach,10,11 and prospective protocols
have demonstrated clinical efﬁcacy of a TREX strategy
in neovascular AMD.12e14 In an Australian, single-arm
analysis, Abedi et al13 were the ﬁrst to report the results of a
prospective TREX protocol of anti-VEGF treatment: in 120
consecutive patients with treatment-naïve neovascular AMD,
excellent visual outcomes were reported, with fewer in-
jections and clinic visits compared with monthly treat-
ments. The current trial directly compares TREX dosing with
ﬁxedmonthly dosing, the gold standard for optimal visual and
anatomic outcomes in neovascular AMD management.Methods
The Treat-and-Extend Protocol in Patients with Wet Age-Related
Macular Degeneration (TREX-AMD) is a phase IIIb, multicenter,
randomized, controlled clinical trial (Food and Drug Administration
investigational new drug identiﬁer, 116786; ClinicalTrials.gov identi-
ﬁer, NCT01648292). Institutional review board/ethics committee
approval was obtained for this Health Insurance Portability and
Accountability Actecompliant trial adhering to the tenets of the
Declaration of Helsinki. Data were collected at Retina Consultants of
Houston (Houston, Katy, and Woodlands, TX) and Palmetto Retina
Center (West Columbia, SC). Inclusion criteria consisted of patients
with treatment-naïve choroidal neovascularization secondary to
exudative AMD with Early Treatment Diabetic Retinopathy Study
(ETDRS) best-corrected visual acuity (BCVA) between 78 and 18
(Snellen equivalent, 20/32e20/500) determined by protocol trial lens
refraction, and total area of subretinal hemorrhage and ﬁbrosis
comprising less than 50% of the total lesion. At enrollment, patients
were randomized sequentially by a blinded study coordinator to the
monthly or TREX cohort and informed consent was obtained. At all
visits, subjects underwent ETDRS BCVA testing at 4 m, slit-lamp and
dilated ophthalmic examination, spectral-domain (SD) optical coher-
ence tomography (OCT), and fundus autoﬂuorescence imaging using
the Heidelberg Spectralis HRAþOCT (Heidelberg Engineering, Hei-
delberg, Germany). The Heidelberg OCT acquisition protocol featured
a volume scan (20  20, 49 lines, 768 A-scans per line) with 9-times
image averaging.
All subjects received 0.05-ml intravitreal injections of ranibizu-
mab (0.5 mg) administered monthly (287 days) for 3 treatments.
Patients in themonthly cohort (n¼ 20) continued to receive monthly
treatments. For patients randomized to TREX (n¼ 40), beginning at
the third monthly treatment, the interval between treatments was
tailored based on exudative disease activity: eyeswere treated at each
visit, no more frequently than every 4 weeks and no less frequently
than every 12 weeks. At each visit, TREX patients were classiﬁed as
having a dry or wet macula and were treated monthly until a dry
macula was achieved (Figs 1 and 2). A dry macula was achieved on2515
Figure 2. Treat-and-extend case example. A, Baseline fundus photograph with spectral-domain (SD) optical coherence tomography (OCT) orientation
(green line), followed by sequential SD OCT images at baseline, visit 6 (week 37), and visit 8 (month 12), illustrating resolution of pigment epithelial
detachment and subsequent recurrence of exudation (visit 6) and resolution of exudation (visit 8). B, Graph showing that as soon as the macula is dry, the
treatment interval is increased sequentially by 2 weeks until exudation is identiﬁed (visit 6); the interval is then reduced until dry (visit 8). BCVA ¼ best-
corrected visual acuity; ETDRS ¼ Early Treatment Diabetic Retinopathy Study.
Ophthalmology Volume 122, Number 12, December 2015resolution of intraretinal and subretinal ﬂuid on SD OCT and
on resolution of subretinal and intraretinal hemorrhage related
to exudative AMD. The presence of a pigment epithelial
detachment without intraretinal or subretinal ﬂuid did not
qualify a macula as wet. When a dry macula was achieved, the
interval between visits was lengthened by 2-week increments. If
recurrent exudative disease activity was identiﬁed and the macula
therefore was wet, the interval between visits was reduced by
2-week increments until a dry macula again was achieved. The
interval between visits then was extended by 1-week increments
until recurrent exudative disease was detected. If a wet macula
was again established, the interval between visits was reduced by
1-week increments until dry, at which point the most recent in-
terval between visits was maintained for 1 additional visit, and if
the macula remained dry, the interval between visits was increased
by 1-week increments again. If an eye exhibited recurrent
exudative disease activity 3 times at a given interval between
visits, treatment was continued at the next shorter interval for 3
consecutive visits, at which time the TREX protocol was reini-
tiated. Given the inherent variability of follow-up intervals using a
TREX protocol, ETDRS BCVA and central (subﬁeld) retinal
thickness (CRT) data from the TREX cohort were plotted longi-
tudinally by combining sequential 4-week intervals.
Sterile techniques were used for every injection. Prophylactic
peri-intravitreal injection topical ophthalmic antibiotics were not
used. Topical anesthetic was instilled and the use of subconjunctival
anesthesia was optional at the investigator’s discretion (2% lido-
caine without epinephrine at the injection site). After topical anes-
thesia, the periocular skin, eyelids, and eyelashes were disinfected
with 10% povidoneeiodine swabs, and 5% povidoneeiodine
ophthalmic solution was applied to the ocular surface. After intra-
vitreal injection, ﬁnger-counting testing was performed to conﬁrm
central retina artery perfusion, and intraocular pressure was
measured 30 minutes after injection. Subjects were monitored until
intraocular pressure measured 30 mmHg or less.
The primary outcome measure was mean ETDRS BCVA
change from baseline. Secondary outcome measures included
mean change in CRT by SD OCT, total number of intravitreal2516injections, percentage of patients with persistent exudative dis-
ease activity by SD OCT, percentage of patients gaining or losing
10 or 15 ETDRS letters at month 12, and the incidence and
severity of ocular and systemic adverse events. The accuracy of
the SD OCT automated segmentation (internal limiting mem-
brane and Bruch’s membrane) was evaluated, and segmentation
errors were corrected manually before computation of change
maps and change in CRT. Of the 3 patients (5%) who did not
complete year 1, corresponding data are included until the date of
study withdrawal. Statistical comparisons were performed with
Student’s t tests and paired Student’s t tests using Statistical
Analysis Software version 9.1.3 (SAS Inc, Cary, NC) where
appropriate. In the current trial with a sample size of 60 patients
randomized 1:2, utilizing a noninferiority limit of 5 ETDRS let-
ters and the 12.5 ETDRS letter standard deviation reported in the
LUCAS trial,14 we calculated an a priori power of 42% to detect
noninferiority (signiﬁcance 5%, one-sided).15 TREX-AMD 1 year
post-hoc analysis demonstrated a power of 88% with a difference
in means between cohorts of 1.3 ETDRS letters and a standard
deviation of 6.1 and 10.9 ETDRS letters for the Monthly and
TREX cohort, respectively.
Fundus autoﬂuorescence images were graded using Region
Finder software version 2.4.3.0 (Heidelberg Engineering) as
described in previous reports.16 Areas with deﬁnitively decreased
autoﬂuorescence were graded as atrophic areas. The foveal
avascular zone and areas with questionable decreased
autoﬂuorescence were guided by corresponding SD OCT B-scans
and infrared images to conﬁrm or refute the presence of atrophy.
Atrophy was identiﬁed on SD OCT B-scans using 3 Doheny
Image Reading Center criteria: increased signal transmission
through the choroid, thinning or disappearance of the retinal
pigment epithelium, and collapse of the outer retinal layers.
Results
Sixty patients were enrolled between February 2013 and January
2014. Baseline demographics were well balanced between patients
Table 1. Baseline Patient Demographics
Female gender (male/female) 63% (22/38)
Mean age (range), yrs 77 (59e96)
Right eye (right eye/left eye) 43% (26/34)
PCIOL (PCIOL/crystalline) 53% (32/28)
DM 18% (11/60)
HTN 78% (47/60)
Mean ETDRS BCVA (range) 60.5 (18e78)
Snellen equivalent (range) 20/60 (20/500e20/32)
Mean CRT (range), mm 511 (265e1007)
BCVA ¼ best-corrected visual acuity; CRT ¼ central retinal thickness;
DM ¼ diabetes mellitus; ETDRS ¼ Early Treatment Diabetic Retinopathy
Study; HTN ¼ hypertension; PCIOL ¼ posterior chamber intraocular lens.
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(Table 1). At baseline, mean age was 77 years (range, 59e96 years),
and 63% (38/60) were women. Baseline mean BCVA was 60.3 and
59.9 ETDRS letters (Snellen equivalent, 20/60) in the monthly and
TREX cohorts, respectively. Baseline mean CRT was thicker in
the monthly cohort (533 vs. 489 mm). Fifty-seven patients (95%)
completed month 12 and 3 patients withdrew consent at weeks 15,
19, and 27 because of temporal arteritis, diagnosis of lung cancer,
and meningitis, respectively. Of 632 possible visits among all
patients, 6 (0.9%) were missed (Supplementary Fig 1; available at
aaojournal.org).
Visual Acuity Outcomes
Mean BCVA gains were similar between cohorts. At month 2, the
end of the mandatory loading phase, mean BCVA improved 4.6
and 5.5 ETDRS letters in the monthly and TREX cohorts,Figure 3. Graph showing visual acuity outcomes. Change in mean best-corre
[ETDRS] letters) in the monthly and treat-and-extend (TREX) cohorts over 1respectively. Mean BCVA gains increased for both cohorts through
month 12: 9.2 and 10.5 for the monthly and TREX cohorts,
respectively (P ¼ 0.60; Fig 3). An intention-to-treat analysis
demonstrated similar results, with an increase of 9.9 letters among
TREX patients (P ¼ 0.76) and no difference among monthly pa-
tients because none of these patients withdrew from the trial before
month 12.
At month 12, 9 patients (45%) and 13 patients (33%) gained 10
ETDRS letters or more, whereas 3 patients (15%) and 10 patients
(25%) gained 15 ETDRS letters or more in the monthly and TREX
cohorts, respectively. At month 12, no patient in the monthly
cohort lost more than 5 ETDRS letters and 3 patients (8%) in
the TREX cohort lost 10 letters, of whom 1 patient (3%) lost
37 letters because of progressive macular atrophy. This 70-year-
old woman initially gained 13 letters with treatment as her macular
edema resolved, but then lost more than 7 lines of vision as central
macular atrophy expanded from approximately 0.32 mm2 at
baseline to 3.36 mm2 at month 12 (Fig 4). The fellow eye
demonstrated advanced dry AMD with no neovascularization
and regions of geographic atrophy expanding from 0.42 to
0.82 mm2 over the same period.Anatomic and Treatment Burden Outcomes
Mean CRT improvements were similar between cohorts. At month
12, there was no statistically signiﬁcant difference in mean CRT be-
tween the groups, with a mean decrease in CRT of 246 mm for the
monthly cohort and 173 mm for the TREX cohort (P ¼ 0.18),
yielding absolute mean CRT of 271 and 290 mm, respectively (Fig 5).
An intention-to-treat analysis demonstrated similar results, with
improvement of172mmamongTREXpatients (P¼ 0.16), yielding
an absolute mean CRT of 285 mm at month 12.cted visual acuity (BCVA; Early Treatment Diabetic Retinopathy Study
2 months. SEM ¼ standard error of the mean.
2517
Figure 4. Treat-and-extend case example of progressive macular atrophy: (A) fundus photographs, (B) infrared imaging with spectral-domain (SD) optical
coherence tomography (OCT) thickness maps, and (C) image-tracked foveal SD OCT line scans as indicated in (B) (green line). Resolution of exudative
disease activity is followed by central macular atrophy at 6 and 12 months. (D) Graph showing visual acuity decreased progressively as atrophic area
increased and the intervals between visits were sequentially maximally extended as the macula remained free of exudative disease activity. BCVA ¼ best-
corrected visual acuity; ETDRS ¼ Early Treatment Diabetic Retinopathy Study.
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tered was 13.0 and 10.1 (range, 7e13) for the monthly and TREX
cohorts, respectively (P < 0.0001). Within the TREX cohort, 27
patients (68%) were extended at the earliest possible visit or within
1 additional visit, 7 (18%) were maximally extended, 4 (10%)
remained wet at every visit, and 12 (30%) remained dry at every
visit after achieving a dry macula. At month 12, 18 patients (45%)
were at an extension interval of 8 weeks or more, and the mean
maximum extension interval was 8.4 weeks among TREX patients
(Fig 6).
Of the 24 TREX patients (60%) who achieved a dry macula
and then demonstrated a wet macula, the extension interval at the
time of a wet macula developing was their maximum extension
interval and was unable to be lengthened when rechallenged in
most eyes (71% [17/24]). Only 3 patients (13%) were able to
maintain a dry macula at an interval of 2 weeks or more beyond
their initial maximal extension interval on rechallenging this
interval.2518Adverse Events
Ocular and systemic adverse events are reported in Table 2. Serious
ocular adverse events included a retinal pigment epithelial tear (n¼
1 at week 4), resulting in loss of 11 ETDRS letters, and worsening
of central macular atrophy (n ¼ 1; Fig 4). There were no cases of
endophthalmitis or intraocular inﬂammation.
Discussion
The TREX approach is the most commonly used treatment
method for neovascular AMD worldwide. Management
using a TREX strategy signiﬁcantly reduces the burden of
care and cost of care delivery,10 and is used by more than
77% of retina specialists afﬁliated with the American
Society of Retina Specialists in the United States.17
In this prospective, randomized, controlled trial, TREX-
AMD, this reduction in treatment burden was signiﬁcant,
Figure 5. Graph showing anatomic outcomes. Change in mean central retinal subﬁeld thickness (spectral-domain optical coherence tomography) in the
monthly and treat-and-extend (TREX) cohorts over 12 months. SEM ¼ standard error of the mean.
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PRN protocol necessitating monthly visits, 3 fewer treatments
using the current strict TREX protocol corresponded to 3 fewer
ofﬁce visits and the associated diagnostic imaging and travel
burdens for patients. Such reduction in treatment burden has
been illustrated in other analyses of TREX dosing.12e14
LUCAS (Lucentis Compared to Avastin Study) is the
largest prospective TREX trial to date, in which 441
patients in Norway were randomized to ranibizumab
(0.5 mg) or bevacizumab (1.25 mg) treatment with a
maximum extension interval of 12 weeks.14 At 1 year, the
ranibizumab and bevacizumab cohorts demonstrated similarFigure 6. Bar graph showing extension intervals in weeks. Interval between visi
The mean maximum extension interval was 8.4 weeks.visual outcomes, gaining 8.2 and 7.9 mean ETDRS
BCVA letters, respectively, with the ranibizumab cohort
requiring statistically signiﬁcantly fewer re-treatments (8.0
vs. 8.9; P ¼ 0.001) and achieving a signiﬁcantly greater
proportion of patients with a dry macula (65.2% vs. 47%;
P < 0.001).14
Compared with prior uncontrolled analyses of TREX
dosing, the current series is a direct prospective compari-
son of monthly and TREX dosing. Mean visual acuity
(VA) gains of 9.2 and 10.5 ETDRS letters in the monthly
and TREX cohorts, respectively, at month 12 are consis-
tent with the registration trials ANCHOR (Ranibizumabts at month 12 among treat-and-extend patients who completed month 12.
2519
Table 2. Ocular and Serious Systemic Adverse Events
Monthly Treat-and-Extend
Ocular AEs
Total AEs 2 (15%) 10 (25%)
Worsening cataract 0 (0%) 4 (10%)
Subconjunctival hemorrhage 1 (5%) 2 (5%)
Epiretinal membrane 1 (5%) 0 (0%)
Progressive macular atrophy 0 (0%) 1 (3%)
Posterior vitreous detachment 0 (0%) 1 (3%)
RPE tear 0 (0%) 1 (3%)
Superﬁcial punctate keratitis 0 (0%) 1 (3%)
Serious SAEs
Total SAEs 0 (0%) 5 (13%)
Congestive heart failure 0 (0%) 1 (3%)
Lung cancer 0 (0%) 1 (3%)
Meningitis 0 (0%) 1 (3%)
Prostate cancer 0 (0%) 1 (3%)
Temporal arteritis 0 (0%) 1 (3%)
AE ¼ adverse event; RPE ¼ retinal pigment epithelium; SAE ¼ systemic
adverse event.
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Degeneration), MARINA (Ranibizumab for Neovascular
Age-Related Macular Degeneration), VIEW1, and VIEW2
(Intravitreal Aﬂibercept [VEGF Trap-Eye] in Wet Age-
related Macular Degeneration).2,3,18 The TREX outcomes
reported by Abedi et al,13 from a single-arm, prospective
analysis involving patients treated with both bevacizumab
and ranibizumab, also indicate comparable visual out-
comes through 2 years compared with monthly dosing in
ANCHOR and MARINA.
Compared with monthly dosing, less absolute visual
gains have been achieved with less frequent dosing using
both PRN strategies4,5 and, more strikingly, ﬁxed-interval
quarterly dosing.19,20 Similarly, even within a TREX strat-
egy, less frequent dosing can result in less optimal visual
gains, as elegantly illustrated in the Fight Retinal Blindness
observational registry involving 1011 neovascular AMD
patients from Australia and New Zealand managed with a
TREX approach.11 Over a 6-year period, although initial
VA remained similar for patients seeking treatment within
each calendar year, VA gains increased in conjunction with
increasing frequency of re-treatment among patients from
sequential years. Arnold et al11 suggested that this
signiﬁcant shift may be a reﬂection of “hardening of re-
treatment criteria” and replacement of time-domain OCT
with SD OCT, thereby improving the sensitivity of exuda-
tive disease activity detection.
Among the TREX cohort of the current trial, the mean
maximum extension interval was 8.4 weeks, and 22% of
patients required monthly dosing, whereas 37% required
treatment at 9-week intervals or longer at month 12. These
are similar proportions to the respective 19% and 34% re-
ported in the Fight Retinal Blindness cohort, which pri-
marily included patients managed with ranibizumab.11 It is
unknown whether a different ranibizumab dose5,21e23 or
alternative anti-VEGF agents such as aﬂibercept3 may yield
different distributions of extension intervals in a similar
patient population.2520No prior prospective TREX protocol has considered
whether an initial maximum extension interval is longitudi-
nally static. In both the current and LUCAS studies,14
treatment intervals were lengthened progressively by 2
weeks until recurrent exudative disease was identiﬁed, at
which point the interval was shortened by 2-week in-
crements until a dry macula was reestablished. The protocols
differ at this juncture: in LUCAS, the maximum ﬁnal interval
then was deﬁned as “2 weeks less than the period when the
previous recurrence was observed,”14 whereas the current
protocol was created to evaluate whether the previous
maximum interval could be lengthened or if indeed it was a
ﬁxed interval beyond which recurrent exudative disease
activity was inevitable. In this trial, 71% of eyes were
unable to achieve an extension interval longer than their
initial maximum extension interval, and only 13% of eyes
were able to maintain a dry macula at an interval at least 2
weeks longer than their initial maximum extension interval.
Muether et al24 reported that the intraindividual aqueous
VEGF suppression period after ranibizumab treatment of
neovascular AMD is remarkably consistent within up to 3
years. In a population of 83 patients with 859 aqueous
samplings, the mean period of complete VEGF suppression
was 36.4 days, ranging from 26 to 69 days.24 These
experimental intraocular VEGF concentration data are com-
plimentary with the current clinical trial data; both indicate a
broad range of individual VEGF suppression times with
remarkable intraindividual stability, supporting a clinical
approach of deﬁning and then maintaining an individual’s
maximum tolerated dosing interval in neovascular AMD
management. Remarkable reproducibility of the intra-
individual need for re-treatment was also identiﬁed by Mantel
et al.25 In that Swiss prospective analysis of 39 AMD patients
retreated with ranibizumab when SD OCT demonstrated
exudative disease activity, minimal intraindividual variability
was reported during 12 months of follow-up, with a standard
deviation ranging from 0 to 2.13 weeks.
Despite excellent outcomes in the current trial, some pa-
tients lost substantial vision, as has been reported elsewhere.26
One patient lost 37 ETDRS letters because of progressive
macular atrophy with a rate of growth that appeared faster
than the published mean of 1.78 mm2 annually in the setting
of geographic atrophy in the Age-Related Eye Disease
Study.27 Although anti-VEGF pharmaceuticals are highly
effective in neovascular AMD, debate exists regarding their
role in the development or progression of macular atrophy.28
This particular case is remarkable because macular atrophy
progressed rapidly while the macula was free of edema and
the interval between anti-VEGF treatments concurrently
was maximally extended. Furthermore, advanced dry AMD
in the fellow eye showed minimal atrophic progression over
the same period.
The strengths of this study are its prospective design
involving well-deﬁned patient cohorts and high protocol
compliance. The limitations of this trial include the inherent
variability of follow-up intervals using a TREX protocol and
associated lack of an absolute ﬁxed end point for all pa-
tients, as well as the limited number of patients.
A TREX approach to neovascular AMD offers the op-
portunity to individualize management while minimizing
Wykoff et al  TREX-AMD 1-Year Resultstreatment burden. Visual and anatomic outcomes with rani-
bizumab appear similar to those with ﬁxed monthly dosing.
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